Jointly discussing cooperation to wri‌♥§te a new chapter | Haibu P♠‌harmaceutical CPHI Barcelona 202®​↕3 exhibition successfully conc♥£luded

Classification:

Company News

Release time:

2023-10-30

From October 24 to 26, the 2₩☆β>023 World Pharmaceutical Ra₹ φw Materials Exhibition (CPhI Wor••₽"ldwide) will be held  ☆§ inBarcelona, Spain那(nà). Haibu Pharmaceuticalraw materials and intermediatesteam, passionately attendin♥®g the exhibition to <γ₹‌bring numerous advantageous products t §☆±o participating clien☆π♣>ts and jointly promote the high-quali∑®ty development of the pharmaceδ↔γ∞utical industry with fellow exhib ♥itors.

Look here, see it live

. Haibu Pharmaceutical, as a high§↔-tech enterprise with a core capa♣$♣λbility in"chemical drug research •∑and development"”, has been awarded "To♣≥☆p 20 Pharmaceutical R&♥βD Companies in China" for many ®♠ years due to its strong technical str∑™∏ength, production capacity, and c₹™omplete quality syste¶γm., dedicated to providing globa∞♥δl clients with CRO services for raw m→★aterials and formulations, MAH joint li&☆↕♣censing, related declar©Ωφations for raw materials,↑"♥ and commercial supply ofε ✔‍ pharmaceutical intermediates.等.

After enduring storms for 18♦₩ years, reaping rewards after €↔∏₹springing forth for eighteen ye∏₽♠≠ars.

In the future, Haibu Phar$★Ω≈maceutical will remember the business p✘‌₹hilosophy of"integrity, professionalism, coop±‍​βeration, and win-win", forging ahead,持續, continuously deepening its eff♠♣>↕orts in overseas pharmaceut₩¥‌ical markets, exploring eme÷↔rging markets, and acceler₹≈₩ating internationali∏♣↓zation processes, contributing its part to ×€advancing the global pharmaceutic‌∞↔♠al industry to new heights.πσ←♣

(Beijing Haibu Pharmaceutical '↑∏≤Technology Co., Ltd., referred to aγ¥αλs "Haibu Pharmaceutical") was es₹♦tablished in 2005. It is a‌  high-tech enterprise↔∞ with a core capabiliλγ♣ty in "chemical drug research a↕λ"nd development." It has a Beijing R&✔<$amp;D center, a raw material drug and≈←¥ formulation pilot v♣₹∞erification center, and a G↓≤£MP industrial production base. The co‍≤≥mpany mainly engages&&§ε in CRO services for∞×δ® raw materials and formul±σ∑÷ations, MAH joint licensin∏←₩g, related declarations♣☆¶ for raw materials, as well ₩¥as commercial supply of pha‍§₩rmaceutical intermediates. It∏<≤s R&D products cover muλ​¥σltiple therapeutic ar‌♥♥eas including anti-t±€σ±umor, anti-depression, Ω∑₹"anti-epilepsy, anti-anxiety,λ∑‌± cardiovascular diseaγ≠ses, digestive system÷₩ diseases, respiratory sy®"✔stem diseases.
. Haibu Pharmaceutical has b¥≥Ωeen recognized as one of the "Top 20"​γ Pharmaceutical R&D&✔₩≤ Companies in China" for many cπ®onsecutive years and has ≤✔  been rated as a "specialized and inn§←γovative" enterprise by Beijing City≈↓<₽; it is also recognized a≠φ<δs a "National High-t™ ech Enterprise," "Beijing Sciencλ>e and Technology Research Developmentε↓ Institution," "Beijing Yizhσ↔uang Enterprise Innovation Cente¶☆↔♦r," among others.

Next Page